Orexo and SVF Vaccines collaborate to explore AmorphOX® formulation of LNP-mRNA vaccines
· News-MedicalOrexo AB and SVF Vaccines AB today announced a research collaboration to investigate whether Orexo’s proprietary powder-based drug delivery technology, AmorphOX®, can be used to develop stable powder-based formulations of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccines.
The collaboration will assess whether LNP-mRNA formulations can be formulated and spray dried using AmorphOX® while preserving critical nanoparticle properties and functional mRNA activity.
LNPs protect mRNA and enable its delivery into cells. However, maintaining the stability of both the mRNA and its lipid carrier presents formulation challenges that can complicate storage and distribution. Powder-based formulations could help address these challenges and allow more flexible handling, transport and storage.
The project brings together Orexo’s expertise in powder formulation and intranasal drug delivery with SVF Vaccines’ expertise in vaccine development. If successful, the initial program could support further development toward intranasal administration, which would require additional evaluation of delivery performance, tolerability and mucosal immune responses.
Nikolaj Sørensen President and CEO, Orexo ABThis collaboration will explore whether AmorphOX® can address an important formulation challenge in mRNA vaccine development, Our initial objective is to establish whether we can develop stable powder-based formulations while preserving LNP integrity and mRNA activity. Positive results would provide a foundation for further development and help us assess the potential of our technology in vaccines and other biologic applications.”
Matti Sällberg, Founder and Chief Scientific Officer of SVF Vaccines commented: “The clinical success of mRNA vaccines has highlighted both the enormous promise and the formulation challenges associated with these technologies. The ability to convert LNP-mRNA formulations into a stable dry powder suitable for nasal administration could represent an important advancement for the field. Intranasal vaccination offers an opportunity to generate immunity where respiratory pathogens enter the body. This collaboration is an important first step toward exploring how our mRNA vaccine expertise and Orexo’s formulation capabilities could support that goal.”
The collaboration forms part of Orexo’s strategy to evaluate AmorphOX® across additional therapeutic areas and molecule classes. Results from the initial feasibility program will inform decisions on subsequent development and potential expansion of the collaboration.
Source: